The Therapeutic Potential of Oral Everolimus for Facial Angiofibromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of Efficacy
This case underscores the efficacy of oral everolimus in reducing FA size in a pediatric TSC patient, with broader therapeutic benefits that support the potential of mTOR inhibition as a multi-targeted strategy for TSC management. Further studies are needed to explore the full range of applications and long-term impact of mTOR inhibitors in TSC care.
Authors
- Shigemi Yoshihara (ORCID: https://orcid.org/0000-0003-2146-1087)
- Kunio Yui (ORCID: https://orcid.org/0000-0002-3714-2956)
- Ken Igawa (ORCID: https://orcid.org/0000-0001-5574-198X)
- George Imataka (ORCID: https://orcid.org/0000-0002-7691-0460)
- Hideaki Shiraishi (ORCID: https://orcid.org/0000-0003-4199-0728)
- Satoshi Mori
Institutions
- Chiba University (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Diseases
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3390/diseases12120334
- Primary Topic
- Tuberous Sclerosis Complex Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Dokkyo Medical University